TaiwanJ Pharmaceuticals Obtained US$26M Deal for Licensing and Co-Development Contract with Newsoara Biopharma on JKB-122 Asian Rights

By In The News
March 8, 2019 in The Headlines

Recommended Posts

In The News

Posted March 8, 2019

- Share

Posted March 8, 2019

HSINCHU, Taiwan, March 8, 2019 /PRNewswire/ -- TaiwanJ Pharmaceuticals has signed a US$26 million contract with Newsoara Biopharma to license out its drug candidate JKB-122 for further development in Asia. On March 2nd, 2019, TaiwanJ announced that its JKB-122, an effective phase 2...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219916
2. Jaydee
  16802
3. Kip Powick
  12213
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.2k
- Total Posts
  
  558.8k

Sign In

TaiwanJ Pharmaceuticals Obtained US$26M Deal for Licensing and Co-Development Contract with Newsoara Biopharma on JKB-122 Asian Rights

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support